Literature DB >> 21823015

Association of expression of Leucine-rich repeats and immunoglobulin-like domains 2 gene with invasiveness of pituitary adenoma.

Huaqiu Zhang1, Qin Yan1, Shutian Xu1, Yibo Ou1, Fei Ye1, Baofeng Wang1, Ting Lei1, Dongsheng Guo2.   

Abstract

The Leucine-rich repeats and immunoglobulin-like domains-2 (LRIG2) gene expression in pituitary adenoma and its correlation with tumor invasiveness were studied. The expression of LRIG2 mRNA and protein in human pituitary adenoma obtained surgically was detected by RT-PCR (39 cases) and immunohistochemical staining (30 cases). It was found that LRIG2 was mostly localized at the nucleus of the pituitary adenoma cells. Its expression was significantly higher in the invasive cases than in the non-invasive cases. LRIG2 protein was positive in 14 cases out of 21 cases of invasive adenoma, but only 2 cases were positive in 9 cases of non-invasive adenoma. The positive expression rate of LRIG2 mRNA was 91.3% in invasive cases (total 23 cases) and 62.5% in non-invasive cases (total 16 cases), respectively. LRIG2 gene is overexpressed in invasive pituitary adenoma. It may play an important role in pituitary adenoma invasiveness and further studies are necessary to elucidate the mechanism under this phenomenon.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21823015     DOI: 10.1007/s11596-011-0483-3

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  25 in total

1.  LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.

Authors:  David L Shattuck; Jamie K Miller; Melanie Laederich; Melanie Funes; Heidi Petersen; Kermit L Carraway; Colleen Sweeney
Journal:  Mol Cell Biol       Date:  2006-12-18       Impact factor: 4.272

Review 2.  Pituitary adenomas: results of 684 surgically treated patients and review of the literature.

Authors:  H H Oruçkaptan; O Senmevsim; O E Ozcan; T Ozgen
Journal:  Surg Neurol       Date:  2000-03

3.  Cloning, characterization, and expression of human LIG1.

Authors:  J Nilsson; C Vallbo; D Guo; I Golovleva; B Hallberg; R Henriksson; H Hedman
Journal:  Biochem Biophys Res Commun       Date:  2001-06-29       Impact factor: 3.575

4.  The transmembrane molecule kekkon 1 acts in a feedback loop to negatively regulate the activity of the Drosophila EGF receptor during oogenesis.

Authors:  C Ghiglione; K L Carraway; L T Amundadottir; R E Boswell; N Perrimon; J B Duffy
Journal:  Cell       Date:  1999-03-19       Impact factor: 41.582

5.  The Drosophila kekkon genes: novel members of both the leucine-rich repeat and immunoglobulin superfamilies expressed in the CNS.

Authors:  M Musacchio; N Perrimon
Journal:  Dev Biol       Date:  1996-08-25       Impact factor: 3.582

6.  Characterization and tissue-specific expression of human LRIG2.

Authors:  Camilla Holmlund; Jonas Nilsson; Dongsheng Guo; Anna Starefeldt; Irina Golovleva; Roger Henriksson; Håkan Hedman
Journal:  Gene       Date:  2004-05-12       Impact factor: 3.688

7.  Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF.

Authors:  Fernanda Ledda; Oliver Bieraugel; Shahrzad Shirazi Fard; Marçal Vilar; Gustavo Paratcha
Journal:  J Neurosci       Date:  2008-01-02       Impact factor: 6.167

8.  RIGging functional outcomes in glioma cells: new insights into LRIG proteins in malignant gliomas.

Authors:  David D Eisenstat; Spencer B Gibson
Journal:  Cancer Biol Ther       Date:  2009-06-16       Impact factor: 4.742

9.  Giant pituitary tumors: a study based on surgical treatment of 118 cases.

Authors:  Atul Goel; Trimurti Nadkarni; Dattatraya Muzumdar; Ketan Desai; Umesh Phalke; Praveen Sharma
Journal:  Surg Neurol       Date:  2004-05

10.  Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro.

Authors:  S S Chaidarun; M C Eggo; M C Sheppard; P M Stewart
Journal:  Endocrinology       Date:  1994-11       Impact factor: 4.736

View more
  4 in total

1.  Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.

Authors:  Shi-Qi Cheng; Heng-Yi Fan; Xin Xu; Wei-Wei Gao; Shi-Gang Lv; Min-Hua Ye; Miao-Jing Wu; Xiao-Li Shen; Zu-Jue Cheng; Xin-Gen Zhu; Yan Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

2.  In vivo analysis of Lrig genes reveals redundant and independent functions in the inner ear.

Authors:  Tony Del Rio; Allison M Nishitani; Wei-Ming Yu; Lisa V Goodrich
Journal:  PLoS Genet       Date:  2013-09-26       Impact factor: 5.917

Review 3.  LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.

Authors:  Y Wang; E J Poulin; R J Coffey
Journal:  Br J Cancer       Date:  2013-04-04       Impact factor: 7.640

4.  LRIG2 expression and prognosis in non-small cell lung cancer.

Authors:  Guangchuan Wang; Jie Wu; Huijuan Song
Journal:  Oncol Lett       Date:  2014-05-19       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.